Cargando…
Predictive value of DOT1L mutations for clinical outcomes in non‐small‐cell lung cancer patients receiving immune checkpoint inhibitor therapy
Autores principales: | Guo, Tianxing, Wang, Zhaofeng, Wang, Song, Zhang, Yaru, Pang, Jiaohui, Ying, Yajun, Ou, Qiuxiang, Shen, Dong, Li, Gang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545889/ https://www.ncbi.nlm.nih.gov/pubmed/37784247 http://dx.doi.org/10.1002/ctm2.1430 |
Ejemplares similares
-
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
por: Yao, Yu, et al.
Publicado: (2023) -
Multi‐cohort analysis identifies somatic NTRK mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma
por: Yan, Junya, et al.
Publicado: (2023) -
Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
por: Bai, Yongkang, et al.
Publicado: (2023) -
Integrated analysis of EGFR mutated non‐small cell lung cancer reveals two distinct molecular subtypes
por: Bai, Menglin, et al.
Publicado: (2023) -
Observations upon the Importance and Value of a Knowledge of the Collateral Branches of Medicine and Surgery, in Connection with Dentistry
por: Robinson, James
Publicado: (1848)